Print Page     Close Window     

SEC Filings

20-F
AC IMMUNE SA filed this Form 20-F on 03/21/2019
Entire Document
 

Convertible Note Agreement | AC Immune SA, 11 December 201815/23

Address for Notices: 

If to Lilly, to: 

Eli Lilly and Company Lilly Corporate Center, 

Indianapolis, IN 46285, U.S.A.;

 

Attention: Robert Paz, Director, R&D Finance

 

with a copy (which shall not constitute notice) to: 

Covington & Burling LLP 

850 10th Street NW

Washington, D.C. 20001 

Attention: Van W. Ellis 

Facsimile: 202-778-5734

 

If to ACI, to: 

AC Immune SA 

EPFL Innovation Park, Building B 

CH-1015 Lausanne, Switzerland 

Attention: Chief Executive Officer

 

with a copy (which shall not constitute notice) to:

 

VISCHER AG 

Aeschenvorstadt 4, 

CH 4051 Basel, Switzerland 

Attention: Dr. Matthias Staehelin 

Facsimile: +41 58 211 33 10

 

10.5.No Waiver

 

The failure of any Party to enforce any of the provisions of this Note Agreement or any rights with respect thereto shall in no way be considered as a waiver of such provisions or rights or in any way to affect the validity of this Note Agreement. The waiver of any breach of this Note Agreement by any Party hereto shall not be construed as a waiver of any other prior or subsequent breach.

 

10.6.Entire Agreement

 

This Note Agreement, its Annexes and the instruments referred to herein, including but not limited to the Note, embodies the entire agreement between the Parties hereto with respect to the Loan contemplated herein. This Note Agreement may be amended only in writing through a document signed by the Parties hereto.

 

10.7.Severability

 

Should any provision of this Note Agreement turn out to be invalid, illegal or unenforceable, the remaining provisions have to be regarded as severable and enforceable in accordance with their terms. The Parties shall replace the partly or entirely invalid, illegal or unenforceable provisions by provisions which are as similar as possible

 

 


© AC Immune 2015